Mar 6, 2014 by Peter StephensCan Merck Outperform AbbVie and Eli Lilly in 2014?After a tough 2013, can Merck come back to beat Eli Lilly and Abbvie this year?
Mar 4, 2014 by Peter StephensCan Pfizer Overcome Its Patent Woes?With patent expiry causing pressure on sales, Pfizer (NYSE: PFE) is attempting an alternative response.
Mar 3, 2014 by Peter StephensHealth-Care Deals Make Explosive Start to 2014 2014 has been a busy year for deal making, with Actavis' purchase of Forest Laboratories being a notable example. But will it get even busier (and bigger)?
Mar 2, 2014 by Peter StephensIs Merck's New Strategy a Winning One?Can changes at Merck (NYSE: MRK) make it a winning stock in 2014?
Mar 2, 2014 by Peter StephensIs Pfizer Doing Enough to Change?Pfizer (NYSE: PFE) is experiencing difficulties with regards to patent expiries. But is it doing enough to combat this?
Mar 1, 2014 by Peter StephensIs Eli Lilly's Bad News Priced In?Challenges from copycat drugs don't seem to be affecting Eli Lilly's (NYSE: LLY) share price. Is the bad news priced in?
Mar 1, 2014 by Peter StephensIs Bristol-Myers Squibb All Set for a Strong 2014?After a great 2013, can Bristol-Myers Squibb (NYSE: BMY) perform as well in 2014?
Mar 1, 2014 by Peter StephensIs 2014 Going to Be GlaxoSmithKline's Year?After a strong 2013, can GlaxoSmithKline perform just as well in 2014?
Feb 26, 2014 by Peter StephensCan Abbott Laboratories Beat Baxter International and Edwards Lifesciences in 2014?After a tough 2013 for Abbott Laboratories (NYSE: ABT), can it beat sector peers Baxter International and Edwards Lifesciences in 2014?
Feb 23, 2014 by Peter StephensWhy Is Allergan Beating the S&P 500?Allergan (NYSE: AGN) is up versus the S&P 500 in 2014 -- especially since its results were released in early February. Here's why that is.
Feb 23, 2014 by Peter StephensCan Celgene Deliver in 2014?Celgene (NASDAQ: CELG) had a strong 2013, but 2014 is not quite going to plan. Can it turn things around?
Feb 21, 2014 by Peter StephensWill Hospira's Lack of a Dividend Hold It Back in 2014?Hospira (NYSE: HSP) currently pays no dividend. Could this mean that shares struggle to keep pace with the S&P 500 this year?
Feb 21, 2014 by Peter StephensCan Boston Scientific Outperform the Index in 2014?Although it may seem unlikely at first glance, Boston Scientific (NYSE: BSX) could beat the wider index this year. Here's why.
Feb 21, 2014 by Peter StephensCan Bristol-Myers Squibb Beat the S&P in 2014?Shares of Bristol-Myers Squibb (NYSE: BMY) have been performing well of late, but can it beat the S&P 500 in 2014?
Feb 21, 2014 by Peter StephensDow Debate: Will Johnson & Johnson Crush Pfizer?Johnson & Johnson and Pfizer are both great stocks, but which will come out ahead in 2014?
Feb 18, 2014 by Peter StephensDow Debate: Can Merck & Co., Inc. Chase Johnson & Johnson In 2014?After a strong start to the year, can Merck (NYSE: MRK) beat Johnson & Johnson (NYSE: JNJ) in 2014?
Feb 18, 2014 by Peter StephensCan Gilead Sciences, Inc. Catch Up With Alexion Pharmaceuticals, Inc. And Biogen Idec?Gilead's share price performance has disappointed compared to sector peers Alexion and Biogen in 2014. Can it catch up?
Feb 17, 2014 by Peter StephensDow Debate: Can Johnson & Johnson Beat UnitedHealth Group in 2014?Will the strong performance of UnitedHealth versus Johnson & Johnson in 2013 be reversed in 2014?
Feb 17, 2014 by Peter StephensDow Debate: Will Pfizer Crush Merck?Pfizer and Merck disappointed in 2013 but have made encouraging starts to 2014. Can Pfizer beat Merck, or vice versa?
Feb 14, 2014 by Peter StephensHere's Why Geron Has Been So Volatile This YearGeron's stock has been on a rollercoaster ride in 2014. Here's why.
